Selvita Group delivers a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating, the introduction of new drugs to the market. Selvita Group offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research.
Selvita Group has experience in several areas of life sciences, and offers the following types of projects:
- Integrated drug discovery projects which include in silico drug design, and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro development.
- Chemistry services, including contract synthesis, synthesis pathway design and optimization, synthesis scale-up, physicochemical analyses including stability studies and impurity profiles, as well as drug form development support.
- Biology services, including assay development, ADME and toxicity studies, DMPK studies, as well as pharmacokinetic and pharmacodynamics analyses.
- Advanced protein modeling solutions, based on our proprietary protein modeling platform, virtual screening and focused library design, as well as other services in computational chemistry.
Selvita's laboratories possess the Good Laboratory Practice (GLP) certificate, as well as the Polish Main Pharmaceutical Inspectorate accreditation.
Selvita also develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Selvita is involved in several research projects at the pre-clinical stage. Our current projects are in the area of oncology and central nervous system.
Projects currently available for partnering:
SEL24 program
SEL24 - SEL24 is a group of compounds which are specific inhibitors of Pim-1 kinase with the first clinical candiate - SEL24-A1 undergoing animal toxicology studies.
- Potentially first-in-class anti-cancer treatment targeting selectively Pim kinases,
- Comprises a 800 compound targeted library of small molecules with novel IP,
- High potency in vitro and in vivo in mouse xenograft models of both hematopoietic and solid tumors,
- Standalone efficacy and confirmed synergistic combinations,
- Mechanism of action confirmed by biomarker analysis in vitro and in vivo,
- Compounds display excellent oral bioavailability and very good pharmacokinetic profiles.
- Dual approach:
- SEL24A: multi-target inhibitors of Pim/CDK/FLT3 kinases -
clinical candidate SEL24-A1 - toxicology studies started in January 2012,
- SEL24B: very selective pan-Pim inhibitors - clinical candidate SEL24-B1,- The first safety and ADMET results point towards a good therapeutic index,
- Clinical candidate to be chosen with a partner in 2012.
SEL103 program
Selvita's SEL103 program is based on novel, orally bioavailable and highly selective small-molecules which have the potential to play role in the treatment of multiple cognitive disorders, including Alzheimer?s disease, dementias, etc.
SEL103 is developed in collaboration with Orion Corporation, Finland. Selvita will be responsible for early research on the program and Orion will take over the pre-clinical and clinical development as well as further commercialization.
SEL103 is expected to enter formal pre-clinical development shortly.
SEL120 program
SEL120 program is comprised of innovative compounds targeting CDK8/CDK9 kinases.
The program is developing discovery stage inhibitors of CDK9/CDK8 kinases:
- targeting mitosis and cancer survival pathways
- strong proof of concept in colorectal cancer and lymphoma (70 ? 80% TGI in mouse xenografts)
- acts stronger on colon cancer cell lines than oxaliplatin in standalone dosing and also acts synergistically with oxaliplatin
- highly selective - on par with erlotinib
- orally bioavailable (70%)
- safe at effective doses
- highly synergistic with Aurora inhibitors and vinblastine
- does not cause polyploidy
SEL128 program
Selvita is seekin a risk sharing collaboration on inhibitors of several novel kinases in cancer, involved with signal transduction and cancer metabolism.
- Selvita has already secured $ 2.5 M in funding for the program from EU grants
- Selvita's expertise with small molecule kinase inhibitors research, development and validation evidenced by SEL24 (Pim), SEL120 (Haspin/CDK9) and SEL113 programs makes us a reliable and proven partner for integrated discovery projects
- proposed novel targets were selected based on literature data that validate their role in cancer development and the aim of the project is development of a first in class therapeutic
- we have already internal hits for several of the possible targets
- given our cost structure, the established academic collaborations and further adjacent grant opportunities we have excellent scientific/commercial return on invested budgets in our programs
- established collaborations with leading scientific institutions (clinical research and academic) guarantee access to patient samples and introduction of personalized medicine concept from the start
- we are open to external ideas and discussion on the desired compound profile and selection of possible targets.
SEL141 program
SEL141 program is comprised of innovative compounds targeting kinases involved in the tau phosphorylation process. All compounds involved are at the discovery stage. This project is developed for the treatment of cognitive disorders, including Alzheimer's disease.
Selvita will be starting the research on this program and is looking for a co-discovery partner that will help us make the most of the concept, the hits and the funding that we have already secured ($ 1.1 M ) in a risk-sharing mode.
Some points that we believe make our proposal quite interesting
- Unmet need in Alzheimer's, especially for disease modifying therapeutics
- Small molecule approach as a preferable way of handling chronic, non-life-threatening disorders at patient's home
- Selvita's expertise with small molecule kinase inhibitors research, development and validation evidenced by SEL24, SEL120 and SEL113 programs
- Selvita's expertise with in neurodegenerative disorders evidenced by SEL103 (symptomatic treatment of AD) partnered with Orion in 2010:
- We have established collaborations with leading scientific institutions in Poland specializing in CNS disorders - we get excellent scientific insight as well as in vitro and animal models from there
- All the proposed targets in the program are novel enough to be still interesting and validated enough in the scientific literature to be promising - we have a complete analysis of that
- All the proposed targets in the program can turn out to be strong enough for disease modifying selective modulation and can result in a first in class drug based on our analysis of the competitive environment that we will gladly share with you
- We are open to discuss the desired profile in detail with your scientists and are open to external ideas. The project will include identification of best possible single target or a combination of tau-phosphorylating kinases as the main guideline for medicinal chemistry efforts
- Selvita has already secured $ 1.1 in funding for the program from EU grants
- We have already some internal hits for three targets from the project
- Given our cost structure, the established academic collaborations and further adjacent grant opportunities we have quite good scientific/commercial return on invested budgets in our programs
Copyright @ 2007-2012 Selvita S.A.
|
